How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism.
Mária JaníčkováTomáš BolekLucia StanciakovaNorbert NagyMarián MokáňMatej SamošPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, and consecutively increase CA-VTE-related morbidity and mortality. In addition, there might be specific clinical problems in the treatment of CA-VTE in patients with oral and facial cancer, such as swallowing difficulties, that might limit the possibilities of oral anticoagulation. Finally, there are limited data regarding the optimal treatment of CA-VTE in patients with oral and facial cancer, and this includes data on novel therapeutic strategies, including the use of direct oral anticoagulants. This article reviews current data on the optimal treatment strategy for CA-VTE in patients with OFC.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- papillary thyroid
- electronic health record
- mental health
- soft tissue
- randomized controlled trial
- atrial fibrillation
- squamous cell carcinoma
- stem cells
- big data
- mesenchymal stem cells
- deep learning
- molecular dynamics
- combination therapy
- bone marrow
- artificial intelligence
- replacement therapy